Stereotaxis (NYSEAMERICAN:STXS) Shares Up 2.5% – Still a Buy?

Stereotaxis Inc. (NYSEAMERICAN:STXS)’s share price was up 2.5% during trading on Thursday . The company traded as high as $2.10 and last traded at $2.08. Approximately 389,670 shares changed hands during mid-day trading, a decline of 20% from the average daily volume of 485,419 shares. The stock had previously closed at $2.03.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on STXS. UBS Group set a $4.00 target price on Stereotaxis in a report on Wednesday, November 5th. Roth Mkm reaffirmed a “buy” rating and issued a $4.00 target price on shares of Stereotaxis in a research report on Wednesday, November 12th. Citizens Jmp began coverage on Stereotaxis in a research note on Tuesday, December 16th. They issued a “market outperform” rating and a $4.00 target price on the stock. Finally, Citigroup began coverage on shares of Stereotaxis in a research report on Tuesday, December 16th. They set an “outperform” rating for the company. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $4.00.

Stereotaxis Stock Performance

The stock has a market capitalization of $194.11 million, a P/E ratio of -7.43 and a beta of 1.44. The business has a 50 day simple moving average of $2.37 and a 200-day simple moving average of $2.62.

Institutional Trading of Stereotaxis

Several institutional investors and hedge funds have recently added to or reduced their stakes in STXS. Warberg Asset Management LLC grew its holdings in shares of Stereotaxis by 260.1% in the 2nd quarter. Warberg Asset Management LLC now owns 1,201,500 shares of the company’s stock worth $2,547,000 after acquiring an additional 867,878 shares during the last quarter. AlphaCentric Advisors LLC acquired a new position in shares of Stereotaxis in the 4th quarter valued at $1,380,000. Two Sigma Investments LP purchased a new position in Stereotaxis in the 3rd quarter worth about $1,125,000. Prescott Group Capital Management L.L.C. increased its stake in Stereotaxis by 44.5% in the 2nd quarter. Prescott Group Capital Management L.L.C. now owns 1,139,252 shares of the company’s stock worth $2,415,000 after purchasing an additional 350,600 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Stereotaxis by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 3,441,091 shares of the company’s stock worth $10,702,000 after buying an additional 138,482 shares during the period. 45.35% of the stock is owned by institutional investors and hedge funds.

Stereotaxis Company Profile

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.